Summary by Moomoo AI
Morgan Stanley has filed an amended Schedule 13G with the United States Securities and Exchange Commission on March 7, 2024, indicating a change in their holdings of Novavax Inc. common stock. As of February 29, 2024, Morgan Stanley reported shared voting power over 2,427,012 shares and shared dispositive power over 2,454,328 shares of Novavax, representing 1.8% of the company's class of securities. This filing signifies that Morgan Stanley no longer holds more than five percent of Novavax's securities, as they have ceased to be the beneficial owner of more than five percent of the class of securities. The filing was made in accordance with Rule 13d-1(b) under the Securities Exchange Act of 1934, and Morgan Stanley has certified that the securities were acquired and are held in the ordinary course of business, not with the purpose of changing or influencing the control of Novavax.